<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01684787</url>
  </required_header>
  <id_info>
    <org_study_id>Miguel Santín</org_study_id>
    <nct_id>NCT01684787</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Treatment for Chronic Hepatitis C With Normal Transaminases in HIV Positive Patients</brief_title>
  <acronym>CONTRA</acronym>
  <official_title>Open Multicentre, Phase IV Study to Evaluate Efficacy and Safety of Pegylated Interferon Alpha-2a (40 KD) Plus Ribavirin for Chronic Hepatitis C With Normal Transaminases in Human Immunodeficiency Virus-infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Miguel Santin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari de Bellvitge</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the current practice patients with normal levels of ALT were not treated. However, a&#xD;
      percentage of patients will present an advanced grade of fibrosis and cirrhosis.&#xD;
&#xD;
      Another reason to treat is the similar response to the treatment than elevated ALT patients&#xD;
      published recently in mono-infected patients.&#xD;
&#xD;
      The investigators have not data concerning the evolution and response to the treatment in&#xD;
      co-infected patients with normal ALT.&#xD;
&#xD;
      In the story of treatment chronic hepatitis C of co-infected patients HCV/HIV, sometimes, it&#xD;
      assumes a behavior similar between mono and co-infected patients and the results are&#xD;
      different.&#xD;
&#xD;
      In the case of normal ALT the investigators do not know if the natural history in co-infected&#xD;
      patients is similar than the mono-infected patients, and also the response of the treatment.&#xD;
&#xD;
      This study prospective and controls is the answer of this question. The main hypothesis is if&#xD;
      the response of treatment in co-infected patients is not inferior than mono-infected&#xD;
      patients.&#xD;
&#xD;
      The objective is to evaluate the efficacy and safety of peginterferon alfa-2a and ribavirin&#xD;
      in HIV positive patients with chronic hepatitis and persistently normal ALT. Every CASE&#xD;
      (patient with normal ALT) will have a CONTROL (patient with elevated ALT), concerning&#xD;
      genotype, gender and hospital.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment of co-infected patients with normal ALT would be very important because the&#xD;
      evolution of cirrhosis in this patients is quicker and frequently than mono-infected&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% patients with RNA-HCV negative</measure>
    <time_frame>24 weeks after treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peginterferon alfa-2a + ribavirin in normal ALT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>peginterferon alfa-2a + ribavirin in elevated ALT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a + ribavirin in normal ALT</intervention_name>
    <description>peginterferon alfa-2a 180 mcg/weekly ribavirin 1000-1200 mg/daily</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Pegasys + ribavirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a + ribavirin in elevated ALT</intervention_name>
    <description>peginterferon alfa-2a 180 mcg/weekly ribavirin 1000-1200 mg/daily</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Pegasys + ribavirin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over 18 years old&#xD;
&#xD;
          -  Hepatitis C co infected with stable HIV-1 and normal ALT (CASE) or elevated levels of&#xD;
             ALT (CONTROL)&#xD;
&#xD;
          -  CD4 &gt; 200 cel/mL&#xD;
&#xD;
          -  Stable anti-retroviral treatment for HIV during at least, the 6 previous months to the&#xD;
             inclusion&#xD;
&#xD;
          -  Negative contraception test&#xD;
&#xD;
          -  Informed consent signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Any previous treatment for CHC&#xD;
&#xD;
          -  Any experimental treatment in the 6 previous weeks to the inclusion&#xD;
&#xD;
          -  Cirrhosis grade B or C (Child-Pugh)&#xD;
&#xD;
          -  Treatment with colony-stimulating factors, didanosine or zidovudine, immunomodulator&#xD;
             therapy, isoniazid, rifampicin, …&#xD;
&#xD;
          -  Hepatic cancer&#xD;
&#xD;
          -  Neutrophils &lt; 1500 cel/mL, Platelets &lt; 70000 cel/mL, Hemoglobin &lt; 11 g/dL (men) or &lt;&#xD;
             12 g/dL (women) previous to inclusion&#xD;
&#xD;
          -  Severe psychiatric illness background&#xD;
&#xD;
          -  Serum creatinin &gt; 1,5 times the upper normal limit&#xD;
&#xD;
          -  Background of Pulmonary or Cardiovascular disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel Santin, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitari of Bellvitge</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Txagorritxu</name>
      <address>
        <city>Vitoria</city>
        <state>Alava</state>
        <zip>01009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorci Sanitari Integral</name>
      <address>
        <city>Hospitalet</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari of Bellvitge</name>
      <address>
        <city>Hospitalet</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Mataró</name>
      <address>
        <city>Mataró</city>
        <state>Barcelona</state>
        <zip>08304</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorci Sanitari de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08227</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Donostia</name>
      <address>
        <city>San Sebastián</city>
        <state>Guipúzcoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Xeral-Cíes</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces</name>
      <address>
        <city>Baracaldo</city>
        <state>Vizcaya</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Jorge</name>
      <address>
        <city>Huesca</city>
        <zip>22004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Joan XXIII</name>
      <address>
        <city>Tarragona</city>
        <zip>43007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>June 11, 2010</study_first_submitted>
  <study_first_submitted_qc>September 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2012</study_first_posted>
  <last_update_submitted>September 12, 2012</last_update_submitted>
  <last_update_submitted_qc>September 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitari de Bellvitge</investigator_affiliation>
    <investigator_full_name>Miguel Santin</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>chronic hepatitis C</keyword>
  <keyword>normal ALT</keyword>
  <keyword>HIV/HCV patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

